Anesthesia and analgesia
-
Anesthesia and analgesia · Jun 1998
Comparative StudyThe effects of propofol on cerebral blood flow velocity and cerebral oxygen extraction during cardiopulmonary bypass.
We investigated the effects of burst-suppression doses of propofol on cerebral blood flow velocity (CBFV), cerebral oxygen extraction (COE), and dynamic autoregulation in 20 patients undergoing cardiac surgery. The experimental procedure was performed during nonpulsatile cardiopulmonary bypass (CPB) with stable hypothermia (32 degrees C) in fentanyl-anesthetized patients. Middle cerebral artery transcranial Doppler flow velocity, right jugular bulb oxygen saturation, and jugular venous pressure (JVP) were continuously measured. Dynamic autoregulation was tested by stepwise changes in mean arterial pressure (MAP) within a range of 40-80 mm Hg by sodium nitroprusside and phenylephrine before (control) and during propofol infusion, with a stable plasma concentration (approximately 9 microg/mL). Propofol induced a 35% decrease in CBFV (P < 0.0001) and a 10% decrease in COE (P < 0.05) compared with control. The slopes of the curves relating CBFV and COE to cerebral perfusion pressure (CPP = MAP - JVP) were less pronounced with propofol (P < 0.01 and P < 0.05, respectively). We conclude that propofol decreases CBFV and improves dynamic autoregulation during moderate hypothermic CPB. Furthermore, during propofol infusion, cerebral blood flow was in excess relative to oxygen demand, as indicated by the decrease in COE. ⋯ In this study, we evaluated the effects of propofol on continuously measured cerebral blood flow velocity (CBFV) and cerebral oxygen extraction as a function of perfusion pressure. Propofol induced 35% and 10% decreases in CBFV and cerebral oxygen extraction, respectively. The slope of the curve relating cerebral perfusion pressure to CBFV decreased with propofol.
-
Anesthesia and analgesia · Jun 1998
Editorial CommentPatient simulator competency testing: ready for takeoff?
-
Anesthesia and analgesia · Jun 1998
Randomized Controlled Trial Clinical TrialConjugated estrogen reduces transfusion and coagulation factor requirements in orthotopic liver transplantation.
We conducted a prospective, randomized study to determine the efficacy of conjugated estrogen in reducing blood product transfusion during orthotopic liver transplantation (OLT). Patients undergoing OLT were included in the study. Only those having a reaction time of more than 30 mm or 15 min (19 -28 mm) on computed thromboelastography (CTEG) at the beginning of surgery were enrolled in the study. Patients were randomized to receive either conjugated estrogen (CE) or placebo. Every patient received a first dose of CE (100 mg i.v.) (20 mL) or placebo (20 mL of isotonic sodium chloride solution) at the beginning of the procedure and a second dose of CE (100 mg i.v.) or 20 mL of placebo (20 mL of isotonic sodium chloride solution) just after reperfusion of the new graft. The two groups were similar in age, weight, requirement for veno-veno bypass, time on veno-veno bypass, CTEG measurement, and preoperative hemoglobin and platelet values. Blood products were given in relation to hematocrit and coagulation (CTEG) variables, which were measured every hour during the surgery. The amount of transfused blood products did not differ in terms of units of cryoprecipitate, but the intraoperative requirements for red blood cells (6 +/- 3 vs 9 +/- 6 U; P = 0.05), platelets (12 +/- 8 U vs 18 +/- 10 U; P = 0.05) and fresh-frozen plasma (3 +/- 3 U vs 6 +/- 4 U; P = 0.001) was significantly less in the estrogen group than in the control group. We conclude that CE is associated with a significant decrease in use of fresh-frozen plasma, platelets, and red blood cells during OLT. ⋯ In this study, we prospectively investigated whether i.v. conjugated estrogen could decrease blood product transfusion during orthotopic liver transplantation. Conjugated estrogen-treated patients received less fresh-frozen plasma, red blood cells, and platelets. In this population of patients, conjugated estrogen can be a useful addition in coagulation management during orthotopic liver transplantation.
-
Anesthesia and analgesia · Jun 1998
Randomized Controlled Trial Comparative Study Clinical TrialBronchial mucus transport velocity in paralyzed anesthetized patients: a comparison of the laryngeal mask airway and cuffed tracheal tube.
We compared bronchial mucus transport velocity (BTV), an index of mucociliary clearance, between the laryngeal mask airway (LMA) and the tracheal tube (TT). Forty patients were studied during propofol anesthesia and muscle relaxation with rocuronium. BTV was measured 10 and 60 min after insertion of the airway device by fiberoptic observation of the movement of methylene blue dye injected onto the dorsal surface of the left main bronchus. BTV for the LMA was similar at 10 and 60 min (13.9 +/- 2.0 and 13.6 +/- 2.1 mm/min, respectively). BTV for the TT was significantly faster at 10 min that at 60 min (13.0 +/- 1.4 vs 6.9 +/- 1.2 mm/min, respectively; P < 0.00001). BTV was similar for both devices at 10 min (TT 13.0 +/- 1.4 mm/min versus LMA 13.9 +/- 2.0 mm/min), but was significantly faster for the LMA than for the TT at 60 min (LMA 13.6 +/- 2.1 mm/min versus TT 6.9 +/- 1.2 mm/min; P < 0.00001). We conclude that the LMA impedes mucociliary clearance less than the TT in anesthetized patients. This may have implications for reducing the risk of retention of secretions, atelectasis, and pulmonary infection. ⋯ This study compares bronchial mucus transport velocity, an index of mucociliary clearance, in anesthetized patients between two airway devices, the cuffed tracheal tube and the laryngeal mask airway. We have shown that the laryngeal mask airway impairs mucociliary clearance less than the tracheal tube. This may have implications for reducing the risk of retention of secretions, atelectasis, and pulmonary infection.